Colibri Transcatheter Aortic Heart Valve System Study

Launched by COLIBRI HEART VALVE LLC · Jul 19, 2019

Keywords

ClinConnect Summary

The Colibri Transcatheter Aortic Heart Valve System Study is a clinical trial looking at a new heart valve treatment for people with severe aortic stenosis, a condition where the heart's aortic valve becomes narrow and makes it hard for the heart to pump blood. This study will involve about 30 patients who are at high risk for surgery due to their age or other health issues. Participants will be treated using a minimally invasive procedure where the new valve is delivered through a blood vessel in the leg.

To be eligible for this trial, participants should be over 75 years old and have symptoms linked to severe aortic stenosis. They must also be evaluated by a specialized heart team that agrees they are at high surgical risk. Patients in the trial will be monitored for up to five years to assess how safe and effective the new valve is, with key focus on their survival and overall health at 30 days, and then at 6 months, 1 year, and beyond. It’s important to note that certain medical conditions may exclude individuals from participating. If you or a loved one are interested, the study team can provide more details on the eligibility criteria and what participation involves.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject of age \> 75 years
• • 2. Subject suffering from severe aortic tricuspid valve stenosis defined as follows: High-gradient aortic stenosis (mean pressure gradient across aortic valve \> 40 mmHg or peak velocity \> 4.0 m/s)
• • 3. Subject has symptomatic aortic valve stenosis with New York Heart Association (NYHA) \> Class II
• • 4. Subject with a documented local Heart Team (HT) agreement of high surgical risk as described in the population
• • 5. ECG-gated Multi-Slice Computed Tomographic (MSCT) measurements determined an aortic annulus \> 22 mm and \< 27.4 mm
• • 6. Subject deemed eligible by a TAVI Centralized Case Review Committee (CRC)
• • 7. Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow-up requirements
• Exclusion Criteria:
• • 1. Arterial aorto-iliac-femoral axis unsuitable for transfemoral access as assessed by conventional angiography and/or multidetector computed tomographic angiography (access vessel diameter incompatible with a 16F sheath introducer)
• • 2. Aortic root anatomy condition or lesion preventing implantation or access to the aortic valve
• • 3. Non-calcific acquired aortic stenosis
• • 4. Native unicuspid/bicuspid aortic valve or congenital aortic valve abnormality
• • 5. Previous implantation of heart valve in any position
• • 6. Severe aortic regurgitation (\> 3+)
• • 7. Severe mitral regurgitation (\> 3+)
• • 8. Severe tricuspid regurgitation (\> 3+)
• • 9. Severe left ventricular dysfunction (Left Ventricular Ejection Fraction (LVEF) \< 30%)
• • 10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
• • 11. Multi-vessel coronary artery disease (CAD) with a Syntax Score or residual Syntax Score \> 22 and/or unprotected left main coronary artery
• • 12. Cardiogenic shock
• • 13. Untreated cardiac conduction disease in need of pacemaker implantation
• • 14. Uncontrolled atrial fibrillation (resting heart rate (HR) \> 120bpm)
• • 15. Active and/or suspicion of endocarditis or ongoing sepsis
• • 16. Blood dyscrasias defined as: leukopenia (White Blood Cells (WBC) \< 1,000/mm3), thrombocytopenia (Platelets (PLT) \< 50,000/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states
• • 17. Evidence of acute myocardial infarction (MI) less than 30 days before signing informed consent
• • 18. Any need for emergency surgery
• • 19. Recent (\< 6 months of signing informed consent) CerebroVascular Accident (CVA) or Transient Ischemic Attack (TIA)
• • 20. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis \< 30 days prior to signing informed consent
• • 21. Any active bleeding that precludes anticoagulation
• • 22. Liver failure (Child-C)
• • 23. End-stage renal disease requiring chronic dialysis or creatinine clearance \< 20cc/min
• • 24. Pulmonary hypertension (systolic pressure \>80mmHg)
• • 25. Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by a Forced Expiratory Volume (FEV1) \< 750cc
• • 26. Refusal of blood transfusion
• • 27. A known hypersensitivity or contraindication to all anticoagulation/anti-platelet regimens (or inability to be anticoagulated for the index procedure), to cobalt chromium, to porcine and/or collagen, to glutaraldehyde or contrast media
• • 28. Any medical, social or psychological condition that in the opinion of the investigator precludes the subject from giving appropriate consent or adherence to the required follow-up procedures
• • 29. Currently participating in another drug or device trial (excluding observational registries) for which the primary endpoint has not been assessed
• • 30. Estimated life expectancy of less than 12 months
• • 31. For females, pregnancy or intention to become pregnant prior to completion of all follow-up procedures
• • 32. Inability to comply with the clinical investigation requirements
• • 33. Subject under judicial protection, tutorship or curatorship (for France only)